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Abstract: 
Title: Audiological  profile in Primary  Sjogren’s Syndrome in an Indian setting  
Objectives  
This is a prospective study to determine the frequency and the profile of hearing loss among 
patients with confirmed diagnosis of primary Sjogren’s  Syndrome (pSS) in an Indian setting. 
Secondary objective is to analyse the correlation between hearing loss and immunological 
variables which includes Anti SS-A antibody, Anti SS-B antibody, Anticardiolipin, Complement 
C3, C4 and Cryoglobulins. 
Literature Review 
 Sjogrens Syndrome is a cell mediated autoimmune disease which primarily affects the exocrine 
glands. The disease primarily affects
 
women, with a very high   female-male ratio of  9:1 and is 
seen in 40-60 years age group (1).  Hearing loss may be the first otological manifestation of this 
autoimmune disease (1). Sensorineural hearing loss (SNHL) is found in half patients with pSS 
and is correlated with presence of anticardiolipin (ACA) antibodies  (1) 
  Most studies done in the western countries ( 2,3,4,5) have shown that  pSS is associated with 
significant sensorineural hearing loss(3). SNHL was found to be associated with disease 
duration, there was no correlation with age, presence of autoantibodies, systemic manifestations 
of disease, or drug therapy. Some of the studies (2,4) showed an association of hearing loss with 
immunological variables such as anti SS-A, anti SS-B, anti-phosholipid antibodies and anti-
nuclear antibodies. This study is undertaken to see if the audiological profile is similar to the 
reported literature. 
  
Methodology  
     All consecutive patients  with established diagnosis of pSS  as per the Modified 
American European Classification Criteria  between 20-60 years attending at the Clinical 
Immunology and Rheumatology OPD of CMC Vellore were referred to the AudioVestibular 
clinic over a period of 10 months. These patients who fit into the inclusion, exclusion criteria 
underwent a history taking with detailed structured questionnaire and ENT examination, 
necessary audiological and blood tests. Frequency of hearing loss, its profile, relationship with 
immunological tests  were analysed. All the data were entered into an excel sheet using 
Microsoft Excel and  was analysed using SPSS version 11.0 
Results and Conclusions: 
The frequency of primary Sjogren’s disease is high in this tertiary care rheumatology clinic in 
this Indian setting. The frequency of audiometrically confirmed hearing loss in pSS  is 78.38 %. 
The commonest type  of hearing loss was minimal to  mild sensorineural hearing loss. The high 
frequencies were more affected than lower frequencies. The commonest tympanometry finding 
was A type curve . Acoustic reflex was absent  in 18.92%. The frequency of hearing loss was 
found to be more in the 1
st
 year after onset of  SS than after 5 year duration. There seems to be 
no co-relation between hearing loss and age, sicca symptoms, systemic symptoms, 
immunological test results in pSS. 
Key words: Primary sjogrens syndrome, hearing loss 
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INTRODUCTION 
 Sjogren’s syndrome   is a common autoimmune disorder affecting 2–3% of the 
adult population (1). This cell mediated immune disorder is characterised by lymphocytic 
infiltration and destruction of the exocrine glands, especially the salivary and lacrimal 
glands, leading to  dry mouth and dry eyes, the hallmark of the disease (1). Ear 
involvement is not uncommon in autoimmune diseases. But only few data on this 
problem in primary Sjogren’s Syndrome (pSS) are available (2). If the autoimmune 
pathology is restricted to the ear, it is known as primary auto immune  ear disease (AIED)  
and if multi systemic, organ non specific auto immune disease involve the inner ear,  it is 
known as secondary AIED which includes Cogan’s syndrome, Sjogrens syndrome (SS), 
Wegner’s granulomatosis, systemic lupus erythematosus and various systemic 
vasculitides (3). Sensorineural hearing loss  (SNHL) was commonly reported as the first 
otologic manifestation of autoimmune diseases like rheumatoid arthritis, systemic lupus 
erythematosus , polyarteritis nodosa  and Wegener granulomatosis(4–8).  Only very few 
studies have analysed hearing loss in pSS.  Previous studies reported hearing loss in  pSS, 
which was mainly SNHL;  Tumaiti et al (2) reported hearing loss in 46%; Trott et al (9) 
reported 21.4%,  Hatzopoulos (10) 36.3% and  Ziavara et al (11)  reported hearing loss in 
22.5% patients. The pathogenesis of immune-mediated SNHL is still not clear. It includes 
immune complex mediated vasculitis in the inner ear (4) and auto antibodies directed 
against inner-ear antigenic epitopes (5). Boulassel et al found that 44% of   patients with 
autoimmune hearing loss had   auto antibodies directed  against  30, 42 and 68 kDa  inner 
ear  proteins in sera. (12) 
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AIMS AND OBJECTIVES OF THE STUDY 
 
1) To determine the frequency and the profile of hearing loss among patients with 
confirmed diagnosis of primary Sjogren’s  Syndrome in an Indian setting. 
2) Secondary objective is to analyse the correlation between hearing loss and 
immunological variables which includes Anti SS-A antibody, Anti SS-B antibody, 
Anticardiolipin, Complement C3, C4 and Cryoglobulins. 
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PRESENT KNOWLEDGE AND REVIEW OF LITERATURE 
  Sjogren’s Syndrome  is   systemic autoimmune disease which mainly affects the 
exocrine glands. It usually presents as persistent dryness of the mouth and eyes due to 
functional impairment of the salivary and lacrimal glands. SS is a cell-mediated immune 
disorder.  If there is no associated systemic autoimmune disease, patients with this 
condition are classified as having pSS (13). The spectrum of the disease includes an 
organ-specific autoimmune disease that is autoimmune exocrinopathy to a systemic 
process with multiple extraglandular manifestations(13).  
 Other exocrine glands, including those of the pancreas, bronchial tree and  
gastrointestinal tract may also be affected . The spectrum of clinical manifestations of 
pSS  is very wide ranging from mucosal dryness, to more systemic complaints, affecting 
mainly the musculoskeletal, pulmonary, renal, neurological  and vascular systems. 
Peripheral nervous system disease, manifests commonly as peripheral sensory neuropathy 
or more rarely as mononeuritis multiplex. (1) 
Prevalence 
Among the two to four  million persons in the United States having 
 
SS (14),   one  
million have an established diagnosis. The disease remains
 
undiagnosed in most cases 
because of the   nonspecific nature of
 
its clinical manifestations. The disease primarily 
affects
 
women, with a very high   female-male ratio of  9:1 (14). This could be because of 
the influence of sex hormones. Androgens has immune suppressor role, but oestrogens act 
as immune-stimulants. It may occur in patients
 
of all ages (10), it  affects  patients in the 
fourth to sixth
 
decades of life. Approximately 60% of SS patients have the disease
 
secondary to an accompanying autoimmune disorder such as rheumatoid
 
arthritis, 
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systemic lupus erythematosus, or systemic
 
sclerosis (14). In a study by Fox et al (2000),  
it was seen that 500,000 to 2 million pSS patients in the United States have hearing loss 
(15). Since 1997, only very few studies have analysed hearing loss in pSS (2) . Hearing 
loss may be the first otological manifestation of this autoimmune disease . Ziavra N et al 
(11) found that 22.5% of pSS patients presented with SNHL of cochlear origin affecting 
mainly the high frequencies. This prevalence was lower than that found out by other 
investigators (2,10). SNHL was found to be associated with disease duration. A 
correlation between SNHL and the duration of the disease was found, while there was no 
correlation with age, systemic manifestations of the disease, presence of auto antibodies 
or drug therapy (10). Primary SS is associated with sensorineural hearing loss affecting 
mainly the high frequencies (2); but clinically significant defects are uncommon. Boki et 
al observed significant differences in hearing loss at 4000 Hz and 8000 Hz and minimal 
hearing loss affecting the lower frequencies. There was no evidence of retro cochlear 
pathology or increased vestibular involvement (16). Tumaiti et al reported sensorineural 
hearing loss in 46% of patients with pSS (2). 
Pathogenesis 
Chronic immune system
 
stimulation is the  basic  pathophysiology of SS . The 
exact mechanism of   the underlying  humoral and cellular
 
autoimmune reactions  is 
unknown.
 
Both T and B lymphocytes are involved. B cell hyper reactivity
 
is manifested as 
hypergammaglobulinemia and circulating
 
auto antibodies. Organ specific auto antibodies 
are produced against the cellular antigens seen in the salivary ducts, nerve cells, thyroid 
gland, erythrocytes, gastric mucosa, pancreas and the prostate. In approximately 60% of 
patients with SS non organ specific auto antibodies are found. These auto antibodies 
include antibodies
 
to the small RNA protein complexes, which includes SS-A and SS-B, 
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rheumatoid factor and  antinuclear antibodies. These
 
auto antibodies contribute to tissue 
dysfunction before inflammation
 
is evident (17). 
Focal lymphocytic infiltrates around the glandular ducts  including lymphocytic 
infiltration of the salivary and 
 
lacrimal glands and  exocrine glands of the respiratory
 
and 
gastrointestinal tracts and vagina is the histopathologic features in SS. The infiltrate 
contains
 
T cells, B cells and plasma cells, with predominant activated
 
CD4
+
 helper T cells. 
T cells produce interleukin  (IL)-2,
 
4, 6, 1, and tumor necrosis factor (TNF) α (18).  20% 
of the  infiltrates  consists of  B cells. These
 
locally produce immunoglobulins. These 
immunoglobulins have auto antibody reactivity (19). The infiltrate in the acinar 
epithelium,
 
leads to glandular dysfunction which manifests as sicca features  and enlarged  
major salivary glands (20).  
The inflammatory processes of pSS occur mainly via glandular
 
epithelial cells. 
These cells  express antigen presenting proteins. These cells can 
  
promote adhesion, and 
co-stimulate T lymphocytes. The antigen-presenting
 
function of epithelial cells is 
enhanced by cytokines like interferon IFN -γ and TNF-α. IFN-γ induces apoptosis of 
salivary gland epithelial cells (SGECs). This is by 
 
up-regulation of the Fas protein. Fas  
protein   is a cell surface receptor.  Its 
 
activation leads to apoptosis (21). The expression 
of CD40 protein is  high in cells of  patients
 
with SS. CD40 can also be induced in SGECs 
by IFN-γ and IL-1β (22). SGECs have important  role in the induction of lymphocytic 
infiltrates in  patients with SS (14)
.  
Immune mediated hearing loss 
Auto immune ear disease (AIED) was defined  by McCabe as a rapidly 
progressive bilateral SNHL that responds to the administration of immunosuppressive 
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agents (23). The concept of autoimmune hearing loss was  first  described  by  Lehnhardt 
in 1958 (24).  He described an antigen  antibody  reaction  in  the hearing organs which
 
improved with steroids. If the pathology is restricted to the ear, it is known as primary 
AIED and if multi systemic, organ non specific auto immune disease involve the inner 
ear, it is known as secondary AIED which includes Cogan’s syndrome, Sjogrens 
syndrome, Wegner’s granulomatosis,  systemic lupus erythematosus and various systemic 
vasculitides (3).  
Pathogenesis of immune mediated hearing loss 
The pathogenesis of immune-mediated sensorineural hearing loss is not clear. It 
includes immune complex mediated vasculitis in the inner ear (4) and auto antibodies 
directed against inner-ear antigenic epitopes (5). Boulassel et al reported that antibodies 
to myelin P0 and beta-actin proteins can be seen in the serum of patients with auto 
immune ear disease. Abnormal expression of these proteins will lead to cellular-signal 
transduction dysfunction leading to various vestibule auditory complications (12). 
Anticardiolipin antibodies may be associated with sudden SNHL in patients with 
autoimmune diseases (25). Tumiati et al reported that  anticardiolipin antibodies may  be 
responsible for SNHL in the pSS (2). Tumaiti et al in their study found that 90% of pSS 
had antibodies to SS-A and 66% had antibodies to SS-B.  All patients with the pSS who 
had SNHL had antibodies to SS-A positive. 64% patients who had SNHL had 
anticardiolipin antibodies compared with 18% patients in the normal hearing group (2). A 
high prevalence of cranial neuropathies resulting from the pSS was generally recognized. 
The symptoms and signs of eighth-nerve disorder in pSS have not been specifically 
sought(26). 
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Ziavara et al had reported SNHL in all the 22.5% patients with hearing loss in 
pSS. All of them had SNHL of cochlear origin (11). Boki et al had reported that none of 
their pSS patents had retrocochlear pathology (16). The deposition of immune complexes 
is considered to be the cause for high prevalence of cranial neuropathy in pSS (2,12,27) 
The deposition of immune complexes in the stria vascularis or in the endolymphatic sac 
via complement activation can cause endolymphatic hydrops leading to vestibular 
symptoms(16). 
In Boulassel et al study on patients with autoimmune hearing loss, 44% of the 
patient’s sera had autoantibodies directed against many inner ear proteins. Of these the 
30, 42 and 68 kDa inner ear proteins were found to be the most reactive. Further studies 
had shown that the 30 and 42 kDa inner ear proteins being the major peripheral myelin 
protein P0 and the beta-actin protein, respectively.  Sequence analysis showed that the 68 
kDa protein is novel. The study findings supported the hypothesis that several populations 
of antibodies contribute to the enhanced immunological activity of  AIED  (12).  Previous 
studies had demonstrated that, 58 kDa protein being extracted from guinea pig or bovine 
inner ear tissue, is the target of antibodies in serum samples from patients with AIED. 
In another study by Boulassel et al, it was confirmed that the 58 kDa inner ear 
protein is the COCH5B2 protein. After separating inner ear proteins by gel 
electrophoresis and studying, it was found that the sequence of amino acids in the first to 
third fragments were identical to the amino acids 526 to 539, 417 to 427 and 396 to 405 
of the COCH5B2 protein. Target protein 58 kDa antibodies in serum samples of AIED 
patients is the COCH5B2 protein. This molecule is highly and specifically expressed in 
the cochlea and vestibule (28). 
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Harris et al using a sterile labyrinthitis showed that inner ear is not an immune 
privileged site (29,30). Inner ear can  generate  local immune response  after local or 
systemic immunisation of the antigen. Through the spiral modiolar vein, cells that 
mediate labyrinthitis enter the scala tympani. Resulting labyrinthitis cause physiologic 
dysfunction, loss of sensory cells ultimately leading to fibrosis and osteogenesis in the 
cochlea. 
The guinea pig model shed light on the specific antibody that binds to 68-kD 
bovine inner ear antigen. This antibody  was found in human with AIED and it binds to 
the inducible form of bovine heat shock protein 70 (HSP-70) (31). The primary antigenic 
epitope of this antibody and its  role in AIED is unclear. 
Nair et al found KHRI-3 a particular antibody, which binds to the supporting cells 
of organ of Corti, 68 to 72- kD antigen of inner ear extract. There was strong evidence 
that  KHRI-3 antibody , and human antibodies can recognize the same inner ear 
supporting cell antigen (32,33).  
Recent data shows that KHRI-3 targets multiple peptides similar to those seen in 
the highly conserved protein CTL2 which is abundantly expressed in inner ear (33). 
CTL2 coprecipitates with cochlin , which is one of the most expressed inner ear protein. 
As cochlin has critical  role in maintaining the structure and function of inner ear, 
mutation can cause cochleovestibulopathy. Cochlin specific serum antibody was elevated 
in AIED patients.  
Animal model study of multisystemic  organ nonspecific autoimmune disease 
showed the increase in auditory thresholds, degeneration of stria vascularis, and the 
deposition of antibodies in the strial capillaries  without any inflammatory response. The 
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etiology of strial degeneration is unknown (34–36). The studies on reversal of hearing 
loss on glucocorticoid and mineralocorticoid administration suggest that alteration of 
local  ion transport in the cochlea can revert the hearing loss (37). 
Studies showed that morphologic changes seen in human temporal bones of 
patients with autoimmune disease is consistent with 2 different pathogenic mechanisms. 
Some bones showed  fibrosis and osteogenesis in the scalae indicating the end stage of 
inflammation. Other bones showed cellular atrophy in the absence of inflammation which 
is suggestive of ischemia. A nonspecific vasculopathy with occlusion of labyrinthine  
artery  without vascular inflammation  and necrosis was seen in case of ischemia (34,36)  
Autoimmune antibodies 
Anti SS-A and Anti SS-B antibodies 
Auto antibodies in the pSS are primarily directed against the Sjogrens 
autoantigens SS-A and SS-B and against IgG rheumatoid factor. The SS-A and SS-B 
autoantigens are composed of a number of antigenic proteins which are coupled to small 
RNA molecules. These RNA-protein particles are present in all human cells. These 
autoantibodies can be detected using counter-immunoelectrophoresis, immunoblotting 
technique, ELISA or RNA precipitation assays. Anti-SS-A antibodies are best detected 
with counter-immunoelectrophoresis .The preferred method of screening for anti SS-B 
antibodies in human sera is immunoblotting technique. Anti SS-A antibodies are found in 
60-70 percentage of patients with SS. But anti SS-A antibodies are not specific markers 
for this disease (38). Anti SS-B antibodies are present in approximately 40 - 50 
percentage of patients with  pSS. Anti SS-B antibodies are more specific than anti SS-A 
antibody (38). The only other disease where the antibody can be detected is systemic 
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lupus erythematosus (15% positive). The possible pathogenetic role and origin of auto 
antibodies in pSS is still not clear. The auto antibodies may be the product of an 
oligoclonal B-cell proliferation.  
Auto antibodies to nuclear antigens in patients with multisystem autoimmune 
disease like pSS are classified into two major groups; auto antibodies to DNA and non 
DNA antigens. The non DNA antigens include antinuclear antibodies to the extractable or 
soluble nuclear antigens. Soluble nuclear antigens are ribonucleoproteins (RNPs) which 
consist of small ribonucleic acid (RNA) molecules attached to non-histone proteins. 
There are three main categories: the U group including U1–U6 small nuclear RNAs, the 
Ro group and the La group. The Ro/SSA antigen is formed of a small nucleocytoplasmic 
RNA protein complex consisting of a 60 kDa protein. 60 kDa protein is associated with 
one of the four human cytoplasmic RNAs (hY1, hY3, hY4, hY5)(39–41).The La/SSB 
antigen consists of a 48-kDa protein
 
 and serves as a termination factor for RNA 
polymerase III(42,43). 
The role of both Ro/SSA and La/SSB specific auto antibodies in the pathogenesis 
of pSS is still not clear. The presence of these auto antibodies in serum is associated, with 
earlier disease onset and longer disease duration and  extraglandular disease 
manifestations like splenomegaly, lymphadenopathy, vasculitis, purpura, lymphocytic 
infiltration of labial salivary glands and recurrent parotid gland enlargement(44–47). 
Pourmand et al
 
had reported a weak correlation between the serum titres of IgA 
antibodies and SS-A and SS-B antigens and oral and ocular sicca symptoms (48). Toker 
et al reported that serum titre of anti SS-A and anti SS-B is correlated positively with dry 
eye symptoms and negatively with tear production and he suggested the possible 
contribution of these autoantibodies to the pathogenesis of exocrinopathy in SS (49). 
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Anti-cardiolipin antibodies (ACA)  
ACA are a form of anti-mitochondrial antibody  directed against cardiolipin. It is  
found in several diseases including antiphospholipid syndrome, Behcet's syndrome, 
systemic lupus erythematosus (SLE), syphilis, livedoid vasculitis, vertebrobasilar 
insufficiency and  idiopathic spontaneous abortion (50–52).    
Anticardiolipin antibodies can be detected using an enzyme linked 
immunosorbent assay (ELISA) immunological test. It screens for the presence of β2 
glycoprotein1 dependent anticardiolipin antibodies (ACA). 
Complements  
Complement proteins are serum enzyme systems which help to mediate 
inflammation. It  helps or ―complements‖ the ability of phagocytic cells and antibodies to 
clear pathogens from body. It is part of the immune system known as the innate immune 
system which is not adaptable and it does not change over the course of an individual's 
lifetime. It can be recruited and then brought into action by the adaptive immune 
system(53). 
More than 25 proteins and protein fragments make up the complement system, 
which includes serum proteins, serosal proteins, and cell membrane receptors etc. The test 
to evaluate entire complement system is known as CH50. The most commonly measured 
complement components are C3 and C4. The measurement of complement helps to 
monitor the disease over time. Complements normally circulate as inactive precursors 
(pro-proteins). Complement proteins are activated by immunologic events on interaction 
with immune complexes. When stimulated by triggers, proteases in the system cleave to 
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specific proteins and   cytokines are released to initiate an amplifying cascade of further 
cleavages. The end result is activation of the cell killing membrane attack complex (53).  
The basic functions of the complements are opsonization (enhancing phagocytosis 
of antigens), chemotaxis (attracting macrophages and neutrophils), Lysis (rupturing 
membranes of foreign cells) and clumping of antigen-bearing agents. The complement 
system  play a role in many diseases with an immune component, like asthma, lupus 
erythematosus, glomerulonephritis, various forms of arthritis, autoimmune heart disease, 
multiple sclerosis, inflammatory bowel disease, and rejection of transplanted 
organs(54,55). Deficiencies of the terminal pathway can predispose to both autoimmune 
diseases and infections. Low C4 level is seen in vasulitis associated with pSS. Vasculitis 
in pSS presents with purpura in the lower legs, low complement(C4) level, and 
cryoglobulin in  the blood. Deposition of immune complex on the vessel wall cause 
destruction of vessel wall leading to complement activation and low complement level in 
blood (56) 
Cryoglobulins 
Cryoglobulins are immunoglobulins which precipitate in vitro at temperatures less 
than 37°C. It can produce organ damage through two different pathways . By vascular 
sludging, mainly in type I cryoglobulinaemia and immune-mediated mechanisms in 
mixed cryoglobulinaemia. Cryoglobulinaemia is associated with many illnesses like 
infections, autoimmune disorders, and malignancies (57) .  
Manel Ramos-Casals et al reported cryoglobulins in the sera of (16%) of patients 
with pSS. Of these  most were IgMκ monoclonal and IgG polyclonal. It was seen that 
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leukocytoclastic cutaneous vasculitis, HCV infection and hypocomplementemia are 
associated with the presence of cryoglobulins in the sera of with pSS patients (58). 
Tzioufas in his study found that 17.4% of the patients with pSS had mixed 
monoclonal cryoglobulinemia during the first evaluation. There was a significant 
correlation between the presence of mixed monoclonal cryoglobulinemia and a higher 
prevalence of autoantibodies to SS-A and  SS-B, and the extraglandular manifestations 
(59).  
Clinical Features 
 SS is an autoimmune disease associated
 
with organ specific and systemic 
autoimmunity. Autoimmune thyroid disease was found
 
in 45% of a series of patients with 
pSS (60). Vascular
 
involvement in these patients  result in peripheral neuropathy,
 
gastrointestinal lesions and glomerulonephritis  (61). Numerous
 
systemic manifestations 
of  pSS  can contribute to difficulty
 
of diagnosis.
 
 
Fatigue 
Severe debilitating fatigue may occur in  50% of
 
patients with pSS.
 
 Patients do 
not feel refreshed on waking up (62).
 
The cause of this fatigue is undetermined. 
Subclinical hypothyroidism
 
 frequently associated with pSS 
 
may contribute to the fatigue. 
Twenty two percentage  of patients with primary SS will have fibromyalgia(63).  
Musculoskeletal Involvement 
Primary SS is often confused
 
with RA clinically. Intermittent  polyarticular
  
arthropathy of  small joints is seen in pSS. At times it may be asymmetrical. Joint 
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deformity and mild erosions may occur. A non erosive arthritis, resembling that of SLE, 
may occur
 
transiently (64). Arthralgias exist in approximately 53% of patients
 
and 
myalgias in 22% of patients with pSS (65). 
Dermatologic Involvement 
Dry skin, skin rashes, burning skin, typical hypersensitivity rash, ulcerative 
lesions, violaceous discoloration of digits, Raynaud phenomenon are the dermatological 
manifestations in SS. Dry skin was found to
 
affect 55% of pSS patients.
 
A study reported  
9 of 70 patients
 
with pSS developed vasculitis involving small or medium-sized
 
vessels;  
of these 8 had involvement of  the skin (61). These dermatological
 
findings are 
differentiated from those of SLE and scleroderma. Mild Raynaud phenomenon may be 
seen in 30% of patients with
 
pSS (14). 
A few patients may have severe pSS, which lead to the development of vasculitis 
and lymphoma in later life. Vasculitis presents with purpura in the lower legs, low 
complement (C4) level, and cryoglobulin in  the blood. Deposition of immune complex 
on the vessel wall cause destruction of vessel wall leading to complement activation and 
low complement level in blood (56). 
Pulmonary Involvement 
Even though common, pulmonary involvement is not clinically
 
significant in 
patients with pSS.
 
 Xerotrachea causes cough, which is the main respiratory
 
symptom. 
Lymphocytic alveolitis, interstitial pneumonitis  pseudolymphoma and fibrosis are other 
potential pulmonary complications. Up to 30% of patients may have subclinical 
pulmonary disease (66).
 
Pulmonary
 
function test may show small-airway obstruction. 
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Gastroenterologic Involvement 
SS patients may have involvement of  entire gastrointestinal
 
tract. Malabsorption 
is caused by lymphocytic infiltrates of the intestine.
  
Esophageal dysmotility
 
has been 
reported in 36% to 90% of patients (67,68). Routine laboratory
 
testing may show mild 
pancreatitis and hepatitis.
 
It should be differentiated from hepatitis C and 
 
autoimmune 
hepatitis. Hepatic involvement is  seen in about 7% of patients.
 
There will be  
antimitochondrial antibodies
 
and abnormal liver enzyme levels. The histopathologic
 
appearance is comparable to that of early  primary biliary
 
cirrhosis (69). 
Renal Involvement  
Patients with pSS may have tubulointerstitial involvement of
 
the kidneys like 
distal renal tubular
 
acidosis, hypercalcinuria, or
 
proximal tubule defects (70–72). 
Pathologic examination shows tubulointerstitial nephritis. Hematuria, proteinuria,
 
and 
renal insufficiency may be manifested in patients
 
who show evidence of glomerular 
lesions. Some of them may
 
progress to nephrotic syndrome.  Patients may develop
 
renal 
vasculitis with hypertension and renal insufficiency (14).
 
 
Neurologic Involvement 
Neurologic disease is one of the common significant systemic manifestations of
 
pSS. It can involve both cranial and
 
peripheral nerves and also the central nervous system. 
An increased prevalence of cranial neuropathies is a consequence of the pSS. Symptoms 
and signs of eighth-nerve disorder have been reported in some of the patients (26). Most 
physicians who regularly treat pSS patients may not routinely ask them about hearing loss 
or test them for audiologically detectable hearing loss (2). In one study, it was found that 
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22% (10/46) had peripheral neuropathy and   it was the presenting
 
clinical feature in 5 
patients (11%). The neuropathy was associated
 
with alterations of the endoneurial 
microvessels. Necrotizing
  
vasculitis was not seen (73). Central nervous system 
involvement is very rare and its incidence
 
is controversial(1). It was reported that, 14 
(46%) out of 30 patients with pSS had sensorineural hearing loss
 
and it was significant
 
in 
5 and  the hearing loss  was correlated with the
 
presence of anticardiolipin antibodies, 
which is suggestive of an underlying
 
autoimmune cause (2) 
Diagnosis of SS  
Clinical Signs and Symptoms 
The spectrum
 
of clinical manifestations of pSS is very broad and many symptoms 
of pSS are nonspecific. SS is  
 
seen more in middle-aged women. So the oral, cutaneous 
and
 
vaginal dryness may initially be attributed to menopause. The sicca 
 
symptoms of  
eyes and mouth may be confused with anxiety and atopic
 
symptoms. Xerostomia
 
symptoms are mainly subjective and are common to many conditions (14).
 
 
Signs of lymphoproliferation include enlargement of the salivary glands, 
splenomegaly, lymphadenopathy, and lung infiltrates. Monitoring of laboratory
 
parameters in these patients may reveal signs of the development of lymphoma. This 
includes leukopenia, anemia, appearance of
 
 monoclonal protein, and loss of specific 
autoantibodies (14). 
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Characteristic Clinical Findings 
In a study, stepwise analysis of individual
 
symptoms in 169 patients with SS and 
44 controls found that  the combined sicca symptoms of mouth, eyes and 
 
sore mouth 
classified  93% of patients
 
with pSS and 97.7% of control subjects (65). 
Ocular Manifestations 
Dry eye is the most important ocular
 
manifestation of pSS. Dry eye symptoms 
manifest as itching, grittiness, or soreness with a normal appearance
 
of eye. Ocular 
complaints also include photosensitivity, eye fatigue, erythema,
 
eye discharge, decreased 
visual acuity and the feeling of a film in the visual field (65).
 
Decreased tear film and abnormal mucus
 
component cause accumulation of thick, 
rope like secretions along
 
the inner canthus. Small superficial corneal epithelial erosions, 
filamentary keratitis, conjunctivitis due to Staphylococcus aureus infection are the ocular 
manifestations. Ocular complications
 
include corneal ulceration, opacification, 
vascularization,
 
and perforation (14).
 
Oral Manifestations 
Even though presenting symptoms of pSS
 
are those of xerostomia, patient may not 
complain
 
of oral dryness. Patient may complain of an unpleas ant taste, crackers, 
soreness, difficulty
 
in  eating or problems
 
in controlling dentures (74). As the disease 
progresses, there will not be the normal pooling
 
of saliva in the floor of the mouth. Oral 
mucosa become glazed, form fine wrinkles, tongue becomes red and lobulated, with 
complete
 
depapillation, tongue stick to the palate causing  clicking
 
quality in  speech (14).  
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Chronic salivary gland inflammation leading
 
to decreased salivary flow can cause dental 
caries (75–77).  Salivary glands produce 1 to 1.5 L of saliva per day.  Saliva contains 
many antimicrobial factors which inhibit bacteria and fungi and salivary glycoproteins 
inhibit microbial attachment to oral epithelium (78–80).  Saliva provides a continuous 
flushing system
 
which keeps the mouth clean preventing bacterial colonization. So 
patients with SS can have an increased risk of periodontal disease, dental caries, and acute 
bacterial (staphylococcal or pneumococcal) sialadenitis. Other oral symptoms include 
soreness, fissuring of tongue, angular cheilitis, candidiasis, accumulation
 
of plaque, 
adherence of
 
food to buccal surfaces, and dysphagia (14).
 
  
Additional Xeroses 
Desiccation
 
of the vagina and vulva cause dyspareunia and pruritus (65). 
Decreased glandular secretions
 
of the respiratory tract lead to dryness of  nose, throat,
 
and 
trachea resulting in persistent hoarseness and chronic,
 
nonproductive cough. Decreased 
secretion from the exocrine glands of 
 
skin leads to skin dryness. Vasculitis in the skin 
manifests as purpura or urticaria. It may be associated with presence
 
of anti SS-A 
antibodies and other systemic manifestations. The most common histologic finding
 
is 
leukocytoclastic vasculitis which is necrotizing
 
neutrophilic inflammation of  dermal 
blood vessels,  
 
resulting in palpable purpura, with raised hemorrhagic
 
skin lesions (14).
 
 
Importance of Diagnostic Accuracy 
An early, accurate diagnosis of pSS can
 
prevent or ensure timely treatment of 
many of the complications
 
of the disease, recognition and
 
treatment of systemic 
complications like interstitial lung disease and malignant
 
lymphoma. A correct diagnosis 
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of pSS depends on recognition of the
 
clinical manifestations, excluding differential
 
diagnoses, and differentiating primary from secondary SS (14). 
Diagnostic Criteria 
Minor salivary gland biopsy has been
 
considered the "gold standard" for the 
diagnosis of SS.  Newer
 
criteria allows classification of SS even without  performing
 
lip 
biopsy. American-European Consensus Committee modified and reapproved the criteria. 
It has almost
 
95% sensitivity and specificity for SS. These criteria
 
include  presence of 
subjective and objective sicca features,
 
antibodies to autoantigens SS-A and SS-B, and 
also the characteristic
 
histopathologic findings in minor salivary glands.  
Modified European Classification criteria assist early
 
and accurate diagnosis of SS  
Modified American European  classification criteria for Sjogrens syndrome (81).  
I. Ocular symptoms: a positive response to at least one of the following questions: 
1.  Have you had daily, persistent, troublesome dry eyes for more than 3 months?     
2.  Do you have a recurrent sensation of sand or gravel in the eyes?     
3.  Do you use tear substitutes more than 3 times a day?     
II. Oral symptoms: a positive response to at least one of the following questions: 
1.  Have you had a daily feeling of dry mouth for more than 3 months?     
2.  Have you had recurrently or persistently swollen salivary glands as an adult?     
3.  Do you frequently drink liquids to aid in swallowing dry food?     
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III. Ocular signs—that is, objective evidence of ocular involvement defined as a positive 
result for at least one of the following two tests: 
1.  Schirmer's I test, performed without anaesthesia (≤5 mm in 5 minutes)     
2. Rose Bengal score or other ocular dye score (≥4 according to van Bijsterveld's scoring        
system)     
IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) 
focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score 
≥1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous 
acini and contain more than 50 lymphocytes) per 4 mm of glandular tissue 
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a 
positive result for at least one of the following diagnostic tests:  
1.  Unstimulated whole salivary flow (≤1.5 ml in 15 minutes)     
2. Parotid sialography showing the presence of  diffuse sialectasias (punctate, cavitary or 
destructive pattern), without evidence of obstruction in the major ducts 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed     
excretion of tracer     
VI. Autoantibodies: presence in the serum of the following autoantibodies: 
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both     
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Revised rules for classification 
For primary SS (81) 
In patients without any potentially associated disease, pSS may be defined as follows: 
a. The presence of any 4 of the 6 items is  indicative of pSS, as long as either item IV 
(Histopathology) or VI (Serology) is positive  
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI)      
Diagnostic Methods 
Assessment of the oral, ocular involvement is essential for
 
the accurate diagnosis 
of SS. Schirmer’s test for eye quantitatively measures tear formation by  placement of a 
filter
 
paper in the lower conjunctival fornix. The  result is positive when  <5 mm of filter 
paper
 
is wet after 5 minutes. Rose
 
bengal scoring test   involves after placement of 25 mL 
of  the rose bengal solution
 
into the inferior fornix of each eye, the patient has to blink
 
twice. Slitlamp examination can detect the destroyed conjunctival epithelium.
. 
The rose 
bengal score, which is  the sum of the scores for damage found seen in  3 regions of the 
eye, is calculated. This score can
 
define the presence of keratoconjunctivitis sicca (14).
 
 
Sialometry is the measurement of unstimulated salivary flow into the tube with 
calibration for 15 minutes. If the flow is > 1.5 mL, it is considered to be normal. It is 
simple and noninvasive. But this test alone cannot distinguish
 
between the causes of 
xerostomia. Other tests to evaluate salivary
 
gland involvement are parotid sialography and 
scintigraphy of the salivary gland.  Gross distortion of pattern of parotid ductules  and  
marked
 
retention of contrast medium on sialogram is seen in patients with SS. Reduced 
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uptake as well as release of technetium Tc
 
99m pertechnetate, according to degree of 
xerostomia and salivary flow rate are the scintigraphic findings in patients
 
with SS
 
(14) 
Minor salivary gland biopsy is a very specific test for assessing
 
the salivary 
component of pSS. After the procedure patient
 
will have temporary soreness, and there 
will be fast healing without
 
much scarring. Focal lymphocytic sialadenitis is a 
characteristic histopathologic feature
 
of SS. It is defined as multiple, dense aggregates of 
more than 1 focus ( 50 lymphocytes) 
 
in the perivascular area or periductal area in the 
most of sampled glands (14).  
Serologic and laboratory findings in SS include
 
diffuse hypergammaglobulinemia 
seen in 80% of patients. These autoantibodies include the immunoglobulins, rheumatoid 
factors, antibodies to
 
the SS-A and SS-B and antinuclear antibodies. Anti SS-A
 
is not 
specific for pSS. Cryoglobulins are present in about 20% of patients
 
with pSS, which 
consist of monoclonal
 
IgM  cryoprecipitable immunoglobulins with rheumatoid factor
 
activity(82) 
The cytoskeleton of the organ of Corti  
The understanding of pathology of cochlea requires information on the 
morphology of the inner ear. The cytoplasm of the cells contain a filamentous network 
forming cytoskeleton. These  intermediate filaments  are  proteins forming the basic 
elements of mammalian cells. They measure 7-14 nm in diameter. There are 5 classes of 
intermediate filaments. These are cytokeratins , desmin filaments, glial filaments, 
neurofilaments and vimentin filaments (83) 
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Immunohistochemical methods revealed the cytoskeleton ,innervations and 
neuronal structures of organ of Corti. All the supporting elements of the organ of Corti 
had cytokeratin including 5,8,18, and 19. These were expressed by the phalangeal 
processes and by their apical  processes    of   inner and outer pillar cells, but  not  by 
Deiters’ cell bodies  and hair cells. A gradient of increased cytokeratin expression was 
seen from the base to apex of cochlea. Only marginal (epithelial) cells expressed 
cytokeratin  in the stria vascularis, and it was uniform in all the coils of cochlea(83). 
Histopathology of organ of Corti in autoimmune hearing loss 
In guinea pig studies, it was seen that there were lymphocytic and  polymorpho 
nuclear infiltrates in the scala tympani in inital period, later thickening of and cellular 
infiltration of round window membrane. This experimental auto immune labyrinthitis had 
remission  after 4 weeks. There was evidence for the passage of antibodies from middle 
ear into perilymph. Harris and Ryan suggested endolymphatic sac as the possible source 
of antibody producing cells and of immunoglobulins. Harris et al also suggested that inner 
ear has got immunological functions including autoimmunity (83).  
Hearing Loss 
Organic causes of hearing loss can be classified into conductive and sensorineural. 
Sensorineural can be either sensory or neural. Neural cause is again divided into 
peripheral which is caused by any lesion of 8
th
 nerve and central which is caused by 
involvement of the central pathways (84). 
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Conductive hearing loss 
Any disease process which interferes with the conduction of sound to reach 
cochlea causes conductive hearing loss . The lesion may be in the external ear, tympanic 
membrane, middle ear or ossicles upto the stapediovestibular joint, or eustachian tube 
dysfunction. Audiometry characteristics include lower frequencies being affected more, 
bone conduction better than air conduction with an air bone gap  which  is not more than 
60dB (84) 
Sensorineural hearing loss (SNHL) 
This results from lesions of the cochlea, 8th nerve or central auditory pathways. 
When lesion involves cochlea it is known as sensory type, when the 8
th
 nerve is involved 
it is known as retrocochlear and when the lesion involves central auditory pathways, it is 
known as central deafness. The audiometric characteristics include hearing loss involving 
higher frequencies, no air bone gap, hearing loss which may exceed 60dB (84) 
Mixed hearing loss 
Elements of both conductive and sensorineural deafness are present in the same 
ear. There is air bone gap indicating conductive element and impairment of bone 
conduction indicating sensorineural loss (84). 
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Degree of hearing loss 
Different classifications exist for the degree of hearing loss. 
Classification of hearing impairment severity (85) 
This scale is the modification of Goodman (1965) by Clark (1981)  
Degree of hearing loss 
-10 -15dB  -            Normal hearing  
16-25dB    -           Slight (minimal) hearing loss        
26-40dB    -           Mild hearing loss 
41-55dB    -           Moderate hearing loss 
56-70dB    -           Moderately severe hearing loss 
71-90dB    -           Severe hearing loss 
 >90dB      -           Profound hearing loss 
95% of population has thresholds between -10 and +10dB hearing level 
As the threshold for hearing increases the ability to understand speech decreases. 
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Audiometric tests to assess hearing 
Hearing of an individual can be assessed by various clinical and audiometric tests. 
 
1. Pure tone audiometry  
Audiometer is an electronic device which produces pure tones. The intensity of 
pure tones can be increased or decreased in 5dB steps. The air conduction and bone 
conduction audiometry is done to determine  degree and type of the hearing loss. The 
modified Hughson-Westlake technique can be used for estimating the thresholds (85). Air 
conduction thresholds are usually measured for tones of 125,250, 500, 1K, 2K, 4K and 
8K Hz and bone conduction thresholds for 250, 500, 1K, 2K and 4 KHz .The amount of 
intensity which has to be raised above normal level is the measure of the degree of 
hearing impairment at that particular frequency. The thresholds are charted in the form of 
a graph known as audiogram. The various degrees of hearing loss were calculated as 
average of the thresholds at 3 frequencies 500,1K and 2K Hz. These 3 frequencies are 
considered to be the most important for understanding speech and therefore the most 
important in estimating the degree of handicap which a particular degree of hearing loss 
can cause (85). The thresholds of bone conduction is a measure of cochlear function. The 
difference between the thresholds for air conduction and bone conduction thresholds is 
known as air bone gap, which is a measure of conductive deafness. Audiometer is 
calibrated in such a way that the hearing of a normal person, both for air and bone 
conduction is at zero dB, and there is no air bone gap. When the difference in air 
conduction thresholds between both ears is more than 40dB or above, the better ear is 
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masked by employing a narrow band noise to the non test ear to avoid getting a shadow 
curve from the non test ear (86). 
 
2. Impedance audiometry  
It is an objective test consisting of 2 components 
1) Tympanometry 
2) Acoustic reflex measurements 
 
Tympanometry 
  When sound strikes the tympanic membrane, a proportion of the sound energy is 
absorbed and the rest is reflected. A stiffer tympanic membrane reflects more of sound 
energy than a compliant one. By changing  pressures in the sealed external auditory canal 
and then measuring the reflected sound energy, the compliance and  stiffness of the 
tympano ossicular system and thus the health or diseased status of the middle ear can be 
assessed. The first classification system of tympanograms described by Liden (1969) ,was 
modified by Jerger et al (1972), which became the most popular descriptive system  being 
used now (86). 
The equipment consists of a probe with 3 channels which snugly fits into external 
auditory canal. Channel1 delivers a tone of 220Hz, Channel 2 picks up the reflected 
sound through a microphone and Channel 3 brings about changes in air pressure in the ear 
28 
 
canal from positive to normal and then to negative. The compliance of tympano ossicular 
system is plotted against various pressure changes in the external ear canal .The different 
types of graphs obtained are called tympanograms which are diagnostic of certain middle 
ear pathologies (86).  
Jerger –Liden classification of tympanogram(86) 
Type A-normal tympanogram 
Type As-Compliance is lower at or near ambient pressure. Seen in fixation of ossicles eg; 
otosclerosis, malleus fixation 
Type Ad- High compliance at or near ambient pressure. Seen in ossicular discontinuity or 
thin and lax tympanic membrane. 
Type B-Flat or dome shaped graph. No change in compliance with pressure changes, seen 
in middle ear fluid or a thick tympanic membrane. 
Type C-Maximum compliance at negative pressure in excess of 100 mm of water. Seen in 
retracted in tympanic membrane and may show some fluid in middle ear. (86) 
Acoustic reflex  
             A loud sound, 70-100 dB above the threshold of hearing of a particular ear, 
causes contraction of stapedial muscles which can be detected by tympanometry. Tone 
can be delivered to one ear and the reflex picked up from same ear or contralateral ear, 
called as ipsilateral or contralateral reflexes. 
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The reflex arc involved in ipsilateral reflex-8
th
 nerveventral cochlear nucleus 
7
th
 nerve nucleus ipsilateral stapedius muscle.  
The reflex arc involved in contrateral reflex- 8
th
 nerveventral cochlear 
nucleuscontralateral medial superior olivary nucleus contralateral  7th nerve nucleus 
contralateral stapedius muscle. The presence of stapedial reflex at lower intensities, 
eg.40 to 60 dB than the usual 70dB indicates recruitment and thus a cochlear type of 
hearing loss. 
If a sustained tone of 500 or 1000Hz, is delivered 10 dB above acoustic reflex 
threshold, for a period of 10 seconds, it brings the reflex amplitude to 50%. This 
abnormal adaptation is known as stapedial reflex decay and is   indicative of 8
th
 nerve 
lesion. 
If ipsilateral reflex is present and contralateral reflex is absent, lesion is in the area 
of crossed pathways in brainstem (87). 
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MATERIALS AND METHODS 
Study Design: Prospective case series 
Study population 
This study was conducted over a period of 10 months (January 2011 to October 
2011) in the Immunology and Rheumatology clinic  and AudioVestibular clinic of ENT 
Department of the Christian Medical College & Hospital (CMCH), Vellore. All 
consecutive patients with confirmed diagnosis of pSS as per the Modified American 
European Classification Criteria,  between age 20-60 years, attending  the Clinical 
Immunology and Rheumatology OPD of CMC Vellore were selected for the study over a 
period of 10 months. All patients with established diagnosis of pSS who satisfied the   
inclusion and exclusion criteria were included in the study. 
Inclusion criteria 
1) Patients with confirmed diagnosis of pSS as per the Modified American European 
Classification Criteria   
2) Age between 20-60 yrs  
Exclusion criteria 
Anyone with a past history of ear disease which are known to cause permanent 
sensory or conductive hearing loss like  
1) Chronic suppurative otitis media 
2) History of intake of ototoxic drugs like aminoglycosides and loop diuretics 
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3) History of head injury 
4) History of ear trauma 
5) History of ear surgery 
6) Otosclerosis 
7) Past history of exposure to loud noise 
Informed consent 
Informed consent was obtained from all patients included in the study. The 
consent form is attached as Appendix 2. Institutional Research Board (IRB) approval was 
obtained from the institution for the conduct of the study (IRB Min .No.7288 dated 
22.9.10.) 
METHODS 
All consecutive patients with confirmed diagnosis of pSS as per the Modified 
American European Classification Criteria between 20-60 years attending at the Clinical 
Immunology and Rheumatology OPD of CMC Vellore were referred to the 
AudioVestibular clinic over a period of 10 months. None of them met the criteria for any 
other connective tissue disease. These patients with established diagnosis of pSS who fit 
into the inclusion, exclusion criteria underwent a history taking with detailed structured 
questionnaire and ENT examination. The patients then underwent necessary audiological 
and blood tests. 
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Audiological investigations included 
Pure tone audiometry  
Impedance audiometry. 
The audiological tests were done in the audiology lab. (Colour plates) 
Blood investigations included 
Anti SS-A antibody 
Anti SS-B antibody  
Anticardiolipin (ACA) 
Complement C3, C4 and 
Cryoglobulins 
Anti SS-A antibody, Anti SS-B antibody and Anticardiolipin tests were done in 
the microbiology lab by ELISA technique and serum Complement C3, C4 were done in 
microbiology lab by nephelometry and dilution method. Cryoglobulins were done in 
biochemistry lab with a fasting blood sample by manual qualitative analysis. Anti SS-A 
<20Ru/ml, anti SS-B <20Ru/ml, ACA <12units/ml, C3 90-180mg/dl, C4 10-40mg/dl  
values were considered in the normal range. 
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Pure Tone Audiometry 
This was done in the acoustically treated sound proof two rooms setting. The pure 
tone audiogram was done using a properly calibrated GSI- 61 clinical audiometer to 
establish hearing loss. The air conduction and bone conduction audiometry was done to 
determine  degree and type of the hearing loss. The various degrees of hearing loss were 
calculated as average of the thresholds at 3 frequencies 500,1K and 2K Hz. These 3 
frequencies are considered to be the most important for understanding speech and 
therefore the most important in estimating the degree of handicap which a particular 
degree of hearing loss can cause. The modified Hughson-Westlake technique was used 
for estimating the thresholds (85). 
Air conduction testing: 
The head phone was placed over the opening of the external auditory canal. The 
ears are tested individually and the better ear is tested first. A series of frequency specific 
pure tones were presented through the ear phones. Patient was asked to respond each time 
he hears the sound stimulus. The audiologist calculated the auditory threshold which is 
defined as the lowest intensity level at which a patient can hear the tone at least 50% of 
the time. The threshold is obtained in dB at regular steps of 1000, 2000, 4000, 8000, 500  
and 250 Hz. The results obtained are plotted on the audiogram sheet. 
Bone conduction testing: 
The bone conduction vibrator is placed on the mastoid process individually and 
hearing thresholds are obtained at various frequencies. The threshold is obtained in dB at 
regular steps of   1000, 2000 and 4000, 500 and 250 Hz. 
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Impedance audiometry  
This includes tympanometry and acoustic reflex testing. The machine used in our 
lab is calibrated GSI Tympstar middle ear analyser impedance audiometer. The headset 
contains an ear phone to be placed on the ear and a probe which is to be inserted snugly 
into the ear canal according to the size of the ear canal. The probe delivers both a sound 
signal tone and changes air pressure towards the tympanic membrane and the middle ear 
system. The probe also picks up the changes in the compliance and delivers those changes 
outwards for recording. 
A pure tone stimulus of 500-4000Hz at 70-100 dB above the pure tone hearing 
threshold is delivered through the ear probe. The stimulus is increased or decreased until 
acoustic reflex threshold is obtained which is reported in dB. For ipsilateral acoustic 
reflex testing, the pure tone is delivered through the probe and muscle contraction is 
recorded in the same ear. For contralateral reflex testing, sound is delivered through head 
phone and muscle contraction is recorded in other ear by a probe placed in it. 
ANALYSIS 
All the data contained in the proforma were entered into an excel sheet using 
Microsoft Excel. Continuous variables like age were summarised using means with 
standard deviations. Categorical variables were described using frequencies with 
percentages. Association between hearing loss and other categorical variables were 
assessed using Chi-Square  test. The data was analysed using SPSS version 11.0 
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RESULTS 
There were 37 patients who were recruited for the study after applying the 
inclusion and exclusion criteria.  
Figure 1  shows the age  distribution.  
The patients were between the age of 20-60 years; 18 were between 20-45 years, 
19 were between 46 - 60 years. The mean age of the study group was 45 years;  36 were 
females and one was a male who was 37 year old. 
 
Figure 1 : Age distribution of 37 patients 
18    ( 49%)
19     ( 51%)
20-45 years
46-60 years
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Clinical presentation 
Table 1 shows the frequency of systemic symptoms patients presented with to the 
clinic: 
Of the 37 patients, 34 (91.89%) had sicca symptoms; dryness of  eye and  mouth. 
The mean duration of sicca symptoms were 24 months with a minimum of 12 months and 
maximum of 180 months. The one male patient in the study group had sicca symptoms 
for 10 years. 
Nineteen (51.35%) complained of foreign body sensation in the eyes. The mean 
duration of the eye symptoms was 24 months, with a range of 6 to 72 months. Of the 37 
patients, 3 (8.11%) had recurrent enlargement of bilateral parotid salivary glands, 18 
(48.65%) complained of multiple joint pains, with a mean duration 48 months. 
Table 1  
Systemic symptoms among the 37 patients 
Systemic symptoms Present Percent 
Dry eye 34 91.89 
Dry mouth 34 91.89 
Recurrent enlargement of 
parotids 
3 8.11 
Multiple joint pain 18 48.65 
 Each patient had more than one symptom 
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The audiovestibular symptoms the patients presented with are shown in Table 2. 
Of the 37 patients, 5 (13.51%) complained of hearing loss. Of these 3 (8.11%) had 
unilateral hearing loss and  2 (5.41%) had bilateral hearing loss. 
Five (13.51%) patients complained of tinnitus. Of these 4 (10.81%) had unilateral 
and 1(2.7%)   bilateral tinnitus. The 5 patients who complained of hearing loss did not 
have tinnitus and the 5 who complained of tinnitus did not have hearing loss. 
Three out of 37 patients (8.11%) complained of vertigo. Of these 2 had 
surrounding rotatory vertigo and 1 had light-headedness. 
Table 2:  Audiovestibular   symptoms among 37 pateints 
 
Audiovestibular symptoms Present Percentage 
Hearing loss 5 13.51 
Tinnitus 5 13.51 
Vertigo 3 8.11 
 Each patient  had more than one audiovestibular symptom 
Among the 37 patients, 34 (91.89%) were on treatment with Hydroxychoroquine 
(HCQ) and 18 (48.65%) on Methotrexate (MTX). The mean duration of HCQ treatment 
was 15 months (range 2 to 84 months). The mean duration of MTX treatment  was 16 
months  (range 3 to 60 months). 
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The co morbidities of the patients are shown in Table 3. 
Six (16.22%) had hypertension, 8 (21.62%) had hypothyroidism and 1(2.7%) had 
dyslipiidemia. None were diabetic. 
Table 3 Comorbidities among 37 patients 
Co morbidity Number Percentage 
Hypertension 6 16.22 
Dyslipidemia 1 2.7 
Hypothyroidism 8 21.62 
Diabetes Mellitus 0 0 
 
Of the 37 patients, 28 had Schirmers test done. Of these, 27 (96.43%)  patients 
had a positive Schirmers test confirming dry eyes; 1(3.57%) patient had negative 
Schirmers Test; in 9 patients Schirmers could not be done. 
Table 4 shows the lip biopsy results. Of the 30 patients who underwent lip biopsy, 
15 (50%) had a grade 4, 14(46.67%) had grade 3 and 1 (3.33%) grade 1 inflammation. 
The only one male patient in our study group had grade 4 inflammation. For 7 (18.92%) 
Lip Biopsy was not done. 
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Table 4  Lip biopsy result in 30 patients 
Test Grade 4 Grade 3 Grade1 Total 
Lip biopsy 15 ( 50% ) 14  (46.67 %) 1 (3.33%) 30 (100%) 
Figure 2 and 3 shows the pure tone audiogram results of the 37 patients in the study. 
29 out of 37 (78.38%) were found to have hearing loss on audiometry.  Of these 
37 patients, 24 (64.85%)  had  minimal, 4 (10.8%) had mild, and 1 (2.7%) had moderate 
hearing loss. 8(21.62%) patients had normal hearing on audiometry.  
Among the 29, 28 had sensorineural and 1 had mixed hearing loss which was of 
moderate severity. 
Of the 29 patients 24 (82.76%) had bilateral and 5(17.24%)  unilateral hearing 
loss.  The only one male patient in this study group had bilateral minimal SNHL. 
 Figure 2: Pure Tone Audiogram result in 37 patients  
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Figure 3: Documented hearing loss among 29 patients  
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Out of the 29 patients with hearing loss, 27 patients had a hearing loss affecting 
high frequencies 4KHz and 8KHz. The average threshold for the high frequencies was 
28.56 dB with a maximum value of 82.5 dB. 
Table 5 and Figure 4 show the results of Impedance testing and acoustic reflex 
testing in the study group respectively. The commonest type of tympanogram was A type, 
found in 83.78% of patients. 
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Table 5: Impedance audiogram results in 37 patients 
Side A As Ad B C Total 
Right 31(83.78%) 2 (5.4%) 3 (8.11%) 0 1(2.7%) 37(100%) 
Left 31(83.78%) 3 (8.11%) 0 2(5.4%) 1(2.7%) 37(100%) 
Acoustic reflexes were absent in 18.92% patients. 
Figure4: Acoustic Reflexes in37patients
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Blood test results are shown in Table 6.  Anti SS-A and anti SS-B tests were done 
in 35 patients and ACA was done in 31 patients. Of the 35 patients, 23(65.71%) had 
positive anti SS-A, 12(34.29%)  had positive anti SS-B. Of the 31 patients, 2 (6.45%) had 
positive ACA titre. 
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Table 7 Blood test results  
Tests Positive Negative Total Not done 
Anti SS-A 23(65.71%) 12(34.29%) 35(100%) 2(5.4%) 
Anti SS-B 12(34.29%) 23(65.71%) 35(100%) 2(5.4%) 
ACA 2(6.45%) 29(93.55 %) 31(100%) 6(16.22%) 
Anti SS-A and anti SS-B antibody result shown in Figure 5A and 5B  
        Of the 35 patients who had anti SSA test done, 23(65.71%) had anti SS-A positive 
(> 20Ru/ml), 12(34.28%)  had negative titres. The mean titre value of anti SS-A was 98.8 
Ru/ml. 
Figure 5A :  Anti SS-A antibody  in 35 patients 
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Of the 35 patients who had anti SS-B test done, 12 ( 34.29 %)  had a positive titre 
(>20Ru/ml) and 23 (65.71%) had a negative titre. Two patients did not have the tests 
done. The mean anti SS-B titre was 68.51Ru/ml.  
Figure :5B Anti SS-B antibody  in 35 patients 
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Of the 31 patients who had anticardiolipin antibody test done, 2(6.45%) had a 
positive titre  (>12 units/ml) and 29(93.55%)  had a negative titre. For 6 patients the test 
could not be done. The mean ACA antibody titre was 3.76 units/ml. 
Serum C3 and C4 results are shown in Table 7 
Of the 34 patients who had this test done, 33 (97.06%) had a normal C3 (90-
180mg/dl) and 30(88.23%) had a normal C4 (10-40mg/dl) level in the serum. Only 1 
patient (2.94%) had a low C3, C4 level,  3(8.82%) had a high C4 level and none had a 
high C3 level. 
Table 8   Serum Complements C3 and C4 test results among 34 patients 
Test Low Normal High Total 
C3 1(2.94%) 33(97.06 %) 0 34(100%) 
C4 1(2.94%) 30 (88.23%) 3(8.82%) 34(100%) 
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Comparison between hearing loss and age group is shown in Figure 6. There were 
no differences in hearing loss between the age groups 20-45 and 46- 60 years (Chi sq 
0.0075, P value = 0.935) 
Figure 6 Comparison between hearing loss and age group among 37 patients 
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loss and of the 3 patients without sicca symptoms, 2 (66.67%) had hearing loss; this 
difference was not significant  (Chi sq 0.2642, P value - 0.607). 
Out of the 18 patients who had multiple joint pains, 12(66.67%) had documented 
hearing loss and of the rest 19 without the symptom, 17 (89.47%) had hearing loss. 
Out of the 34 patients who had complained of sicca symptoms, 27(79.41%) had 
documented hearing loss. Out of the 5 patients with sicca symptoms of >5 years duration, 
all of them had documented hearing loss. 
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Out of the 16 patients with dry eye of 1-5 year duration, 11( 68.75 %) had 
documented hearing loss and of the 18 patients with dry mouth  of 1-5 year duration, 13   
( 72.22 %) had documented hearing loss. 
Out of the 13 patients with dry eye of < 1 year duration, 11 ( 84.62 %) and  of the 
11 patients with dry mouth of < 1 year duration ,9 ( 81.82 %)  had documented hearing 
loss . 
There was no significant difference between healing loss with sicca symptoms for 
different duration (Chi square 2.6240,  P value = 0.269 and Chi sq 1.9043 ,P value=0.386 
for comparison with dry eye and dry mouth respectively) 
Out of the 9 patients with Foreign body sensation of eye of < 1 year duration, 8 
(88.89%) had documented hearing loss. 
Of the 9 with same symptom of 1-5 year duration, 5 (55.56 %) had documented 
hearing loss and the only 1 patient who had the symptom of >5 year duration had 
documented hearing loss. This difference in hearing loss between patients with different 
duration of the symptom was not statistically significant. ( Chi sq 2.9556, P=0.228) 
 
The results of comparison between the duration since the onset of disease and 
presence of hearing loss are shown in Figure 7. 
Out of the 11 patients who had the duration of first symptom of SS for more than 
5 years, 8(72.73%) had documented hearing loss.  
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Out of the 17 patients who had the duration of first symptom of SS between 1-5 
years, 13 (76.47 %) had documented hearing loss. 
Out of the 9 patients who had the duration of first symptom of SS of less than 1 
year,  8 (88.89 %) had documented hearing loss. This difference in hearing hearing loss 
between patients with different duration of disease was not found to be statistically 
different. (Chi sq 0.8305, P=0.660) 
Figure 7 Comparison between the duration since the onset of disease and presence of 
hearing loss in 29 patients with documented hearing loss. 
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The comparison between audiometry proven hearing loss and hearing loss 
symptom are shown in Figure 8. 
Out of the 29 patients with documented hearing loss, only 5(17.24%) patients 
complained of a decreased hearing. Rest 24(82.76%) were not aware that they had  
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decreased hearing. All the 5 patients who complained of a decreased hearing had a 
documented hearing loss.  
Figure 8 Comparison between audiometry proven hearing loss and hearing loss 
symptom among 29 with documented hearing loss.  
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Comparison between hearing loss and treatment with HCQ is shown in Figure 9 
Out of 34 patients on HCQ, 27 (79.41%) had hearing loss on audiometry and of 
the rest 3 who were not on HCQ, 2 (66.67%) had hearing loss. This difference in hearing 
loss between patients on treatment and not on treatment  with HCQ was not significantly 
different (Chi sq 0.2642, P = 0.607)  
Figure 9   Comparison between hearing loss and treatment with HCQ among  37 
patients  
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Out of the 4 patients who were on HCQ for more than 5 years, 3(75%) had 
documented hearing loss. 
Out of the 13 patients who were on HCQ for a period between 1-5 years, 
10(76.92%) had documented hearing loss . 
Out of the 17 who were on HCQ for less than 1 year, 14(82.35%) had documented 
hearing loss. The difference in hearing loss between patients on HCQ for difeerent 
duration was not significantly different.(Chi sq 0.1868, P value = 0.911) 
 Of the 18 patients who were on MTX, 12 (66.67 %) had documented hearing loss. 
Out of the 19 who were not on MTX, 17 (89.47 %) had documented hearing loss. 
 The only one patient on MTX for more than 5 years had documented hearing loss. 
 Out of the 8 patients on MTX for a period between 1-5 years, 4 (62.5%) had 
documented hearing loss. Out of 9 patients on MTX for less than 1 year duration, 6 
(66.67%) had documented hearing loss. This difference in hearing loss between patients 
on HCQ for different duration was not found to be significantly different. (Chi sq 0.5625, 
P value 0.755, was statistically not significant. Same issue here 
Out of the 15 patients with a grade 4 lip biopsy, 10 (66.67%) had documented 
hearing loss. 
Out of 14 patients with a grade 3 lip biopsy, 13 (92.86%)  and only one patient 
with grade 1 lip biopsy also  had a documented hearing loss. 
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Comparison between hearing loss and anti SS- A positivity is shown in Figure 10. 
Out of the 22 patients with positive Anti-SS-A titre, 19 (86.36 %) had documented 
hearing loss. Out of 12 patients with Negative Anti-SSA titre, 9 (75 %) had documented 
hearing loss.  
Out of the 27 patients with documented hearing loss, 19 ( 70.37 %) had positive 
anti-SS-A titre. Out of the 7 patients with normal   hearing, 4 (57.14%) had positive anti 
SS-A titre. The difference in hearing loss between those who are positive and negative for 
anti SS-A was not found to be significantly different. (Chi-sq 0.2208; P value =0.453). 
Figure 10 Comparison between hearing loss and anti SS-A positivity among 37 
patients 
 
 
  
86.36%
75%
13.64%
25%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
Anti SSA positive Anti SSA negative
Documented HL
Normal hearing
53 
 
Comparison between hearing loss and anti SS-B positivity is shown in figure 11. 
Out of the 12 patients with positive Anti-SSB titre, 9 (75 %) had documented 
hearing loss. 
Out of 23 patients with Negative Anti-SSB titre 18 (78.26 %) had documented 
hearing loss.  
Out of the 27 patients with documented hearing loss, 9 (33.33 %) had positive 
anti-SSB titre. Out of the 8 patients with normal documented hearing, 3(37.50%) had 
positive anti SSB titre . The difference in hearing loss between those who are positive and 
negative for anti SSB was not found to be significantly different  (Chi-sq 0.0476; P value 
=0.827). 
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Figure 11 Comparison between hearing loss and anti SS-B positivity among 37 
patients  
 
 
 
Out of the 2 patients who had positive anticardiolipin titre, 1(50%) had unilateral 
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levels, 23(79.31%) had hearing loss. This difference was not statistically significant (Chi 
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Table 9 summarises the sicca symptoms, diagnostic tests done and the pure tone  
audiogram result of all the 37 patients. 
Table 9: Sicca symptoms, diagnostic tests done and the pure tone  audiogram result 
of  37 patients. 
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1 Bilateral minimal SNHL + + NA 4 + + 
2 Bilateral minimal SNHL + + NA 4 + - 
3 Bilateral minimal SNHL + + + 3 - - 
4 Bilateral minimal SNHL + + NA 4 + + 
5 Bilateral minimal SNHL + + + 3 - - 
6 Bilateral minimal SNHL + + NA 4 + + 
7 Bilateral minimal SNHL + - + 4 + - 
8 Unilateral minimal SNHL + + + 4 NA NA 
9 Unilateral minimal SNHL + + + 3 - - 
10 Bilateral minimal SNHL + + + 3 + - 
11 Unilateral mild SNHL + + + 3 - - 
12 Unilateral mild SNHL + + + 1 + + 
13 Bilateral minimal SNHL + + NA 3 + + 
14 Bilateral minimal SNHL + + + 4 + + 
15 Bilateral minimal SNHL + + + 3 - - 
16 Bilateral minimal SNHL + + + NA + + 
17 Bilateral minimal SNHL + + NA 3 + - 
18 Unilateral minimal SNHL + - + 3 - - 
19 Normal hearing + + + NA + - 
20 Bilateral minimal SNHL + + + 4 + - 
21 Normal hearing + + + 4 - - 
22 Normal hearing + + + 4 + - 
56 
 
S
. 
N
o
 
D
o
cu
m
en
te
d
 
h
ea
ri
n
g
 l
o
ss
 
D
ry
 e
y
e 
D
ry
 m
o
u
th
 
S
ch
ir
m
er
’s
 t
es
t 
L
ip
 b
io
p
sy
 g
ra
d
e 
A
n
ti
 S
S
-A
 
A
n
ti
 S
S
-B
 
23 Bilateral minimal SNHL + + + 3 + + 
24 Normal hearing + + + 4 - - 
25 Unilateral minimal SNHL + + + 3 - - 
26 Bilateral mild SNHL + + NA 4 + - 
27 Bilateral minimal SNHL + + + 3 - - 
28 Bilateral minimal SNHL + + NA 4 + + 
29 Bilateral minimal SNHL + + + NA + + 
30 Bilateral moderate hearing loss + + + 3 - - 
31 Normal hearing + + + 3 - - 
32 Bilateral minimal SNHL + + + NA + - 
33 Bilateral minimal NSNHL + + NA 4 + - 
34 Bilateral minimal SNHL + + + NA + + 
35 Bilateral mild SNHL + + + NA + - 
36 Normal hearing + + + NA + + 
37 Normal hearing + + + 4 + + 
 
For sicca symptoms,  
+   =   Present;  -  =   Absent 
For anti SS-A and anti SS-B,  
+   =   Positive;  -  =   Negative 
NA = the test is not done.  
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DISCUSSION 
In our study, there was a higher rate of recruitment compared to earlier studies 
from other countries, [Hatzopoulos 2002 / (11), Tumaiti 1997/ (2)]. This perhaps is due to 
this centre being a large tertiary care centre with a very wide catchment and referral for 
large parts of the country. The mean age of patients recruited in this study (45 years) was 
considerably lower than other studies [(55 years), Tumaiti 1997/ (2)]. In keeping with 
what is known in literature, all but one of the patients in this study were women.  The 
influence of sex hormones on pSS has been discussed in the literature reviewed (10). 
Androgens have an immune suppressor role, but oestrogens act as immune-stimulants 
(10).  
Duration of illness is a reflection of access to specialist services. In our situation, 
patients reported within a mean duration of 4.5 years, compared to some other studies 
reviewed; Ziavara et al  (11)  8.3 years, Hatzopoulos et al (10)  mean duration of disease 
for 3 years. 
Symptomatically, in comparison with other studies, a large proportion (92%) of 
our study patients presented with sicca symptoms, 14% with hearing loss and tinnitus. 
Doig et al (88) , showed marginally fewer with similar symptoms (82% with sicca, 4.5% 
with hearing loss and tinnitus). Vestibular involvement in patients with pSS is relatively 
rare; Boki et al (16) did not  find  significant   vestibular involvement while this study  
had 8% patients with history of vertigo.  
Only very few studies have analysed hearing loss in pSS. This study had 78% 
while other studies,  Tumaiti et al (2) reported hearing loss in 46%; Trott et al (9) reported 
21.4%,  Hatzopoulos (10) 36.3% and  Ziavara et al (11)   reported hearing loss in 22.5% 
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patients. SNHL was the commonest hearing loss in this study (97%) and is similar to 
other studies reviewd.   Hatzopoulos  (11)  reported  SNHL in all his patients with hearing 
loss,  Tumaiti et al  reported SNHL in all but one patient in their series,  as did   Ziavara et 
al  (15) in all with hearing loss. While Doig et al were the only study reporting conductive 
hearing loss in their patients (5 out of 22 patients with hearing loss) . While the suggested 
cause of conductive hearing loss is dryness of the mucous membranes of the Eustachian 
tube and middle ear, it should be noted that their study was done before the clear criteria 
for the diagnosis of the pSS were established by the criteria according to the Modified 
American European European Classification (81). 
There was a predominance of bilateral hearing loss (82.8%) in our study similar to 
finding in Tumaiti’s study (71.43%).  Ziavara et al found 44% had bilateral hearing loss 
and   56% of patients had unilateral hearing loss.  This bilaterality may suggest the 
underlying autoimmune pathology (23).  
There is a difference in the severity of SNHL between this study and that of 
others. In this study, out of 29 with hearing loss, all but one patient had minimal to mild 
SNHL, classified on the basis of average pure tone threshold for speech frequencies of 
500, 1000, and 2000 Hz (88). Tumaiti et al  found that out of 15 patients with hearing 
loss, 9 had minimal hearing loss, 4 had moderate hearing loss and 1 had severe hearing 
loss  and  one had mild hearing loss. 
In accordance with earlier studies, our study showed hearing loss mainly affects 
the high frequencies in pSS. It was seen that out of 37 patients, 72.97% patients had a 
hearing loss affecting high frequencies 4 KHz and 8 KHz. The average threshold for 4 
KHz and 8 KHz was 28.56 dB with a maximum of 82.5 dB.  Ziavra  et al (11) found that 
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all patients with hearing loss  had SNHL affecting mainly the high frequencies. Boki et al 
(16) had reported significant hearing loss at 4KHz and 8KHz and minimal hearing loss 
affecting the lower frequencies. Tumaiti et al (2)  had found that out of the 14 patients 
with SNHL, 12 had sloping audiogram involving high frequencies from 2KHz to 4 KHz.  
We found no correlation between documented hearing loss and age. This was also 
reported by Hatzopoulos and Tumaiti in pSS. Ziavara et al (11) concluded that SNHL is 
found to be associated with disease duration. Tumaiti et al (2) and Hatzopoulos (10) 
found no statistically significant difference between disease duration between patients 
with abnormal hearing and those with normal hearing. In contrast to all these previous 
studies we have observed a different trend of improvement of hearing with the duration of 
disease. When we assessed the presence of hearing loss in 3 groups divided based on the 
duration of disease as <1 year, 1-5 years and >5 years, it was observed that  as the 
duration of disease increases, the number of patients with hearing loss decreases. 
However this difference was not significant (Chi sq = 0.8305 and P value = 0.660) . It 
may be postulated that this trend may be because of hearing improvement over the course 
of the disease or because of decreased disease activity due to treatment, which may reflect 
in the pathogenesis of hearing loss as well. It can also be attributed to the small number of 
patients in each group we compared.  A larger sample size may clarify this suggestion. 
The commonest type of tympanogram observed in our study was A type 
(83.78%). In contrast with the data reported by  Hatzopoulos(10) who found that all their 
22 patients with pSS had a normal tympanogram, a small proportion (16.22%) of this 
study had As, Ad, B and C types of curves also. Reflexes were absent in seven patients 
(18.9%) in contrast to Hatzopoulos whose cases all had reflexes present. Tumaiti et al 
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found middle-ear pressure to be normal in all their patients and there were no significant 
differences in mean compliance value between controls and the patients with SS. 
Out of the 29 patients in our study, with documented hearing loss, only 5(17.24%) 
patients complained of a decreased hearing. Rest 24 (82.76%) did not complain of 
decreased hearing. Tumaiti et al found that 9 of 14 (64.28%) with hearing loss were 
asymptomatic and they had hearing loss that was detectable only on audiometry.  
Diog et al (88) found that among 27% of their patients with hearing loss, none 
complained of decreased hearing. In our study, there were a higher proportion of 
asymptomatic hearing loss compared to Tumaiti et al(2). Hearing loss may be the first 
audiological manifestation of pSS (10).  The detection of SNHL in these patients, points 
to the probability of autoimmune involvement of the ear in this multisystemic 
autoimmune disease. So it is important to note that hearing evaluation should be made a 
part of the routine work up of Primary SS patients.  
Duration of treatment with HCQ did not significantly change the proportion of 
patients with hearing loss. This may suggest that HCQ has little adverse effect on hearing 
in patient with SS.  
 This study found 65.71% had antibodies to anti SS-A.  Tumaiti et al (2) found 
that 90% of their patients  had antibodies to SS-A  and it was seen that all patients who 
had SNHL had antiSS-A  positive . Ziavara et al (11)  found no correlation between 
hearing loss and the presence of auto-antibodies. In our study,  86.4 % of patients positive 
for anti-SSA titre had hearing loss.  Presence or absence of hearing loss was not found to 
be associated with anti SSA  positivity in this study.  Anti SS-A antibodies are seen in 60-
70 percentage of patients with pSS. But these are not specific markers of the disease (38).     
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Tumaiti et al found 66% patients with antibodies to SS-B. In our study, 75% of 
patients positive for anti-SSB titre had hearing loss. Presence or absence of hearing loss 
was not found to be associated with anti SSB positivity in this study. Anti SS-B 
antibodies are seen in 40-50 percentage of patients with pSS and these are   more specific 
than anti SS-A (38). 
  Compared to Tumaiti et al study, this study group had a very low proportion with 
ACA antibodies.  ACA is seen in 16% of patients with pSS (41). It was seen that the 
frequency with which ACA is detected in pSS ranged from 6% to 52% (89,90).  Tumaiti 
et al reported out of 9 (40%) of their patients  with  positive  ACA,  9 (75%) had  SNHL 
(2). They suggested the possible biological association between ACA and SNHL which is 
suggestive of an underlying
 
autoimmune pathology. In contrary to that we found that 
hearing loss had no correlation with presence or absence of ACA. Of the 2 patients 
(6.45%) with positive ACA titre, 1(50%) had SNHL.  Ziavara N et al also did not find 
any correlation between hearing loss and presence of ACA. ACA may be associated with 
sudden SNHL in patients with autoimmune diseases (25). The one male patient in our 
study group had all the 3 serological tests anti SS-A, anti SS-B and ACA positive and he 
had bilateral  SNHL. 
Tumaiti et al (2)  did not find any correlation between hearing loss and C3 and C4 
levels as was also seen in our study. The one patient in this study group who had 
vasculitis and low C3 and C4 level, had unilateral  SNHL.  
Cryoglobulins are detected in about 20% of patients
 
with pSS (73). But in this 
study cryoglobulin was not detected in any.   
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The pathogenesis of immune-mediated SNHL is still not clear. It includes immune 
complex mediated vasculitis in the inner ear (4) and auto antibodies directed against 
inner-ear antigenic epitopes (5). The deposition of immune complexes is considered to be 
the cause for high prevalence of cranial neuropathy in pSS (27,28). The deposition of 
immune complexes in the stria vascularis or in the endolymphatic sac via complement 
activation can cause endolymphatic hydrops leading to vestibular symptoms (16,91). This 
is a preliminary analysis to find the audiological profile of patients with pSS. Further 
studies are necessary to establish the probable etiologies in this common autoimmune 
multi-systemic condition.  
Limitations of the study 
Audiological evaluation in pSS patients prior to starting of treatment would have 
provided more information on the disease process without modification by medication. 
This is not possible in a tertiary care situation where patients have already been under 
treatment from other centres for years.  
Further audiological evaluation for identifying the site of pathology on the 
patients detected with hearing loss could not be done due to lack of funds. Such an 
evaluation would have been helpful in explaining the pathology of the disease process. 
It would have been useful to do serial audiological tests to see the progress of 
hearing loss over time in the same patient. That would have provided a greater insight 
into the natural history of hearing loss in pSS. 
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                                           Conclusions 
 The frequency of primary Sjogren’s disease is high in this tertiary care 
rheumatology clinic in this Indian setting. 
 The frequency of audiometrically confirmed hearing loss in Primary Sjogren’s is 
78.38 %. 
 The commonest type  of hearing loss was minimal to  mild sensorineural hearing 
loss 
 The high frequencies were more affected than lower frequencies 
 The commonest tympanometry finding was A type curve  
 Acoustic reflex was absent  in 18.92% 
 The frequency of hearing loss was found to be more in the 1st year after onset of  
SS than after 5 year duration.  
 There seems to be no co-relation between hearing loss and age, sicca symptoms, 
systemic symptoms, immunological test results in primary Sjogren’s  syndrome 
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APPENDIX 1 
Patient Information sheet  
Study Title-   Audiological profile of patients with confirmed diagnosis of Sjogren’s 
Syndrome (SS) in an Indian setting. 
SS is an immune disease affecting mainly some of the glands in the body. Studies in the 
western countries have shown that hearing is affected in about 40 to 50 percent of patients 
with this disease. It is more common in women than in men.  There are no studies done in 
Indian population about the hearing problems in patients who have SS. 
The Rheumatology and Audio vestibular Units are conducting a study to see the extend of 
hearing problems in Indian patients with SS.  
What do you have to do? 
You will be asked to answer a questionnaire and undergo a detail Ear, Nose and Throat 
examination. Then you will have to do two tests - Pure Tone Audiometry and Impedance 
Audiometry are painless and cause no discomfort.  
 Pure Tone Audiometry-This is a simple, non invasive, painless test to determine the  type 
and degree of hearing loss using an electronic device called Audiometer. 
Impedance Audiometry-This is a simple, non-invasive, painless test to find out the health 
status of middle ear using an ear probe with 3 channels.  
All these tests are routine and will not result in any extra cost or harm you in any way. 
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The benefit of this study to you is that if you complain of hearing loss, it can be evaluated 
and treated accordingly and if you do not complain of hearing loss, early hearing loss can 
be diagnosed and measures can be taken to prevent worsening of hearing.  
Your participation in the study is voluntary and you are free to withdraw at any time, 
without giving any reason. As the study doesn’t include any trial treatment, there is no 
extra risk for you due to your participation in the study. There is absolutely no additional 
cost to you as a result of participation in this study. 
 If you are willing to participate in this study, you will be required to sign in the following 
consent form. 
Contact Person 
Dr. Thanooja CV 
Dept of ENT, 
CMC Vellore 
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APPENDIX 2 
Informed Consent form to participate in an observational study 
Study Title-   Audiological profile of patients with confirmed diagnosis of Sjogrens 
Syndrome (SS) in an Indian setting. 
Study Number: 
Subject’s Initials:  
Subject’s Name:  
Date of Birth / Age: 
Please put your signature here 
(Subject) 
i. I confirm that I have read and understood the information sheet dated   for the 
above study and have had the opportunity to ask questions.  
ii. I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected.  
iii. I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw 
from the trial. I agree to this access. However, I understand that my identity will 
not be revealed in any information released to third parties or published.  
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iv. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s)  
v. I agree to take part in the above study.  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:       
Date:  
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: 
Name of the Witness: _____________________________ 
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Appendix 3 
PROFORMA 
 
Audiological profile in Sjogren’s syndrome in an Indian setting 
Serial Number : 
Name :  
Age 
Sex :                                            Hospital number : 
Occupation :                                 Contact number : 
Address:                                                     email Id: 
Date of interview- 
Symptoms present at onset 
Dry eye-                                                                    Foreign body sensation eye- 
Dry mouth-                                                                Persistent salivary gland swelling-  
Duration since onset of first symptom of Sjogrens syndrome- 
History of hearing loss –Yes/No 
                                        Rt/ Lt/ B/L 
If yes duration-  
Sudden/ Progressive/ Gradually progressive 
History of tinnitus - Yes/No 
                                Rt/ Lt/ B/L 
If yes duration- 
History of vertigo-Yes/No 
If yes duration- 
Any other ear symptoms- 
Drugs    -Chloroquine Yes/ No           duration- 
       Methotrexate - Yes/ No               duration- 
       Other drugs- 
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Any other medical conditions present-(HT/DM/Hypothyroidism/Dyslipidaemia) 
If yes on treatment?-Yes/No 
Any family history of similar complaint?i.e.Sjogrens syndrome/other autoimmune conditions?- 
EXAMINATION 
Ear- 
Nose and throat if any symptoms present- 
Neuro ontological examination if indicated- 
INVESTIGATIONS 
Pre morbid audiogram- Yes/ No 
Pure Tone Audiogram-                                Rt (AC/BC)                                    Lt(AC/BC)                         
250   
500 
1000 
2000 
4000 
8000 
Current Audiogram - (date)                  Rt(AC/BC)                                              Lt(AC/BC)                         
250   
500 
1000 
2000 
4000 
8000 
Impedance 
Tympanogram   (date)                                         Rt                         Lt 
 Type of curve 
  Volume 
Reflex                                        Present/Absent                    Present/Absent 
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Serological parameters 
C3 
C4 
Cryoglobulin 
SSA 
SSB 
Anticardiolipin 
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Colour plates 
Figure 12: Audio meter  
 
Figure 13: Tympano meter  
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Figure 14: Pure Tone Audiometry 
 
 
Figure 15: Tympanometry  
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1 Ashrukana Das 61 1 739724d 1 12 3 1 12 4 1 12 0 0 2 18 18 0 0 0 0 0 0 0 0 0 3 1 
2 Sovamal paharia 47 1 459368c 1 120 3 1 120 4 1 60 0 0 1 120 120 1 24 2 1 0 0 0 0 0 24 1 
3 Kokila 55 1 065781d 1 48 1 1 48 3 0 0 0 0 1 120 120 0 0 0 0 1 60 1 0 0 36 1 
4 Padmavathy.P 28 1 747872d 1 6 3 1 6 4 1 6 0 0 0 0 6 0 0 0 0 0 0 0 0 0 4 1 
5 Vinita srivastava 38 1 196869d 1 24 1 1 24 3 0 0 0 0 1 48 48 0 0 0 0 0 0 0 0 0 36 1 
6 Muthusami K 37 2 363755d 1 120 3 1 120 4 1 12 0 0 0 0 120 0 0 0 0 0 0 0 0 0 12 1 
7 Minati saha 45 1 660043d 1 12 1 0 0 4 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 9 1 
8 Lalitha 40 1 674455a 1 48 3 1 48 4 0 0 0 0 0 0 48 0 0 0 0 0 0 0 0 0 24 1 
9 Urmila 43 1 390697d 0 0 1 1 24 3 0 0 0 0 0 0 36 0 0 0 0 0 0 0 0 0 36 1 
10 Suparna Ray 37 1 741102d 1 48 1 1 24 3 0 0 0 0 0 0 48 0 0 0 0 0 0 0 0 0 6 1 
11 Vanithamani 55 1 085203c 1 6 1 1 6 3 0 0 0 0 0 0 6 0 0 0 0 0 0 0 1 72 6 1 
12 Dr.Bhagyalakshmi 53 1 970995d 1 48 1 1 48 1 0 0 0 0 0 0 48 1 48 2 3 0 0 0 0 0 0 0 
13 Susila Devi 60 1 925569d 1 180 3 1 180 3 0 0 0 0 0 0 180 0 0 0 0 0 0 0 0 0 2 1 
13 Valliyammal 55 1 894487d 1 36 1 1 36 4 0 0 0 0 0 0 36 0 0 0 0 1 24 2 0 0 36 1 
15 Angeline Jwbaseline 62 1 957591d 1 7 1 1 12 3 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 
16 Regina 50 1 163142a 1 1 1 1 54 0 1 48 1 48 0 0 54 0 0 0 0 1 1 1 1 6 48 1 
17 Bineeta kumari 35 1 502844d 1 24 3 1 24 3 0 0 0 0 1 24 24 0 0 0 0 1 7 3 0 0 18 1 
18 Shipra saha 38 1 684959c 1 12 1 0 0 3 1 12 0 0 0 0 12 1 12 2 1 0 0 0 0 0 12 1 
19 Santhi 40 1 902681d 1 12 1 1 12 0 0 0 0 0 1 24 24 0 0 0 0 0 0 0 0 0 3 1 
20 Jeeva 37 1 029338b 1 3 1 1 3 4 0 0 1 3 1 48 48 0 0 0 0 0 0 0 0 0 6 1 
21 Arati das 53 1 750635d 1 60 1 1 60 4 0 0 0 0 1 120 120 0 0 0 0 0 0 0 0 0 84 1 
22 Pushpavathy 43 1 872526d 1 12 1 1 12 4 0 0 0 0 1 12 12 0 0 0 0 0 0 0 0 0 6 1 
23 Kalpana 26 1 628271d 1 24 1 1 24 3 0 0 0 0 1 24 24 0 0 0 0 0 0 0 0 0 24 1 
24 Shakila 50 1 094937d 0 0 1 0 0 4 1 12 0 0 1 84 84 0 0 0 0 1 12 1 0 0 24 0 
25 Sree mathini 61 1 1066126a 1 72 1 1 72 3 0 0 0 0 1 48 72 0 0 0 0 0 0 0 0 0 60 1 
26 Pratima 38 1 947537d 1 12 3 1 12 4 1 12 0 0 1 96 96 0 0 0 0 0 0 0 0 0 3 1 
27 Sujatha 33 1 835030b 1 7 1 1 6 3 1 7 0 0 1 7 7 0 0 0 0 0 0 0 0 0 7 1 
28 Punam devi 46 1 566756d 1 24 3 1 24 4 1 24 0 0 1 120 120 0 0 0 0 0 0 0 0 0 24 1 
29 Punithavathy 63 1 412449 1 24 1 1 24 0 1 24 0 0 1 180 180 1 12 2 2 0 0 0 0 0 24 1 
30 Girijasathya 48 1 386513a 1 36 1 1 36 3 1 36 0 0 1 42 42 0 0 0 0 0 0 0 0 0 36 1 
31 Parvathy Devi 36 1 682948d 1 36 1 1 36 3 1 36 0 0 1 36 36 0 0 0 0 0 0 0 0 0 24 1 
32 Mohana 53 1 886316c 1 72 1 1 72 0 1 72 0 0 1 72 72 1 12 2 3 0 0 0 0 0 60 1 
33 Mohini J 42 1 059637f 1 6 0 1 6 4 1 6 0 0 0 0 6 0 0 0 0 0 0 0 0 0 5 1 
34 Gangabai 51 1 672117d 1 12 1 1 12 0 1 12 0 0 0 0 12 0 0 0 0 0 0 0 0 0 6 1 
35 Imbavally 55 1 1905756d 1 24 1 1 24 0 1 24 0 0 2 24 24 0 0 0 0 0 0 0 0 0 7 1 
36 Nallammal 53 1 167370d 1 60 1 1 60 0 1 60 0 0 0 0 60 0 0 0 0 0 0 0 0 0 36 1 
37 Roshan Ara 28 1 846852d 1 24 1 1 24 4 1 24 1 2 0 0 24 0 0 0 0 0 0 0 1 12 6 1 
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1 3 0 0 0 0 1 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 30 30 1 25 
2 24 1 8 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 30 20 40 30 40 35 1 35 
3 36 1 36 1 120 0 0 0 0 0 0 10 10 10 10 10 10 20 20 20 20 10 10 20 20 20 20 20 20 20 20 30 30 1 25 
4 4 0 0 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 25 20 0 22.5 
5 36 1 36 0 0 0 0 0 0 0 0 20 20 20 20 15 15 15 15 15 15 15 15 10 10 10 10 20 20 20 20 30 30 1 25 
6 12 1 24 0 0 0 0 0 0 0 0 25 25 20 20 25 25 20 20 25 25 25 25 20 20 20 20 35 35 35 35 40 40 1 37.5 
7 9 0 0 1 60 1 36 0 0 0 0 20 20 15 15 20 20 20 20 15 15 15 15 20 20 20 20 30 30 15 15 50 30 1 40 
8 24 0 0 0 0 0 0 0 0 0 0 20 20 15 15 20 20 15 15 15 15 10 10 20 20 20 20 15 15 40 40 40 35 1 27.5 
9 36 0 0 1 180 1 180 0 0 0 0 20 20 20 20 15 15 15 15 15 15 15 15 20 20 15 15 20 20 20 20 20 25 1 20 
10 6 0 0 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 15 15 15 15 15 15 15 15 20 20 20 20 20 20 1 20 
11 6 0 0 0 0 0 0 0 0 0 0 40 10 70 0 35 10 70 0 25 15 55 0 30 30 60 35 25 25 55 30 45 55 1 35 
12 0 0 0 0 0 0 0 0 0 0 0 20 20 40 40 20 20 35 35 15 15 25 25 15 15 25 25 15 15 20 20 20 30 1 17.5 
13 2 0 0 0 0 1 180 0 0 0 0 10 10 10 10 10 10 10 15 15 15 15 15 15 15 15 15 30 30 30 30 30 40 1 30 
13 36 0 0 0 0 1 96 0 0 0 0 15 15 10 10 15 15 10 10 15 15 10 10 30 30 30 30 30 30 30 30 20 20 1 25 
15 0 0 0 0 0 1 36 0 0 0 0 20 20 30 30 20 20 20 20 20 20 20 20 20 20 15 15 20 20 20 20 30 20 0 25 
16 48 0 0 1 96 0 0 0 0 0 0 20 20 20 20 20 20 15 15 20 20 15 15 15 15 20 20 20 20 15 15 35 35 1 27.5 
17 18 0 0 0 0 0 0 0 0 0 0 15 15 15 15 15 15 15 15 20 20 20 20 20 20 20 20 20 20 20 20 20 30 1 20 
18 12 0 0 0 0 0 0 0 0 1 48 15 15 15 15 15 15 20 20 10 10 15 15 20 20 20 20 30 30 20 20 15 10 0 22.5 
19 3 1 3 0 0 0 0 0 0 0 0 15 15 20 20 15 15 15 15 15 15 15 15 15 15 15 15 15 15 10 10 35 35 1 25 
20 6 0 0 0 0 0 0 0 0 0 0 15 15 15 15 20 20 20 20 20 20 20 20 20 20 20 20 20 20 15 15 20 15 0 20 
21 84 0 0 0 0 0 0 0 0 0 0 10 10 15 15 10 10 10 10 15 15 15 15 10 10 15 15 30 30 30 30 20 20 1 25 
22 6 1 6 0 0 0 0 0 0 0 0 15 15 15 15 15 15 15 15 15 15 15 15 15 15 10 10 40 40 35 35 20 20 1 30 
23 24 0 0 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 15 15 15 15 20 20 30 30 20 40 1 20 
24 0 1 24 1 24 1 24 0 0 0 0 20 20 20 20 15 15 15 15 20 20 10 10 10 10 15 15 15 15 10 10 25 15 0 20 
25 60 0 0 1 72 0 0 0 0 0 0 10 10 15 15 10 10 20 20 10 10 20 20 10 10 15 15 10 10 15 15 10 15 0 10 
26 3 1 3 0 0 0 0 0 0 0 0 25 25 25 25 25 25 25 25 25 25 25 25 30 30 30 30 20 20 20 20 20 20 0 20 
27 7 1 7 0 0 0 0 0 0 0 0 15 15 15 15 15 15 20 20 20 20 15 15 15 15 15 15 15 15 15 15 15 20 0 15 
28 24 1 24 0 0 1 120 0 0 0 0 20 20 20 20 10 10 20 20 10 10 15 15 10 10 10 10 10 10 5 5 15 5 0 12.5 
29 24 1 24 0 0 0 0 0 0 0 0 35 20 20 20 30 30 20 20 20 20 20 20 20 20 20 20 30 20 15 15 20 25 1 25 
30 36 1 36 0 0 0 0 0 0 0 0 20 0 40 10 20 10 45 20 25 15 45 20 50 40 50 40 60 50 80 50 100 90 1 80 
31 24 1 24 0 0 0 0 0 0 0 0 15 15 10 10 10 10 10 10 5 5 5 5 5 5 5 5 15 15 10 10 25 25 1 20 
32 60 1 60 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 30 40 1 25 
33 5 1 5 0 0 0 0 0 0 0 0 15 15 15 15 15 15 15 15 20 20 20 20 20 20 20 20 30 20 20 20 45 55 1 37.5 
34 6 1 6 0 0 0 0 0 0 0 0 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 30 20 30 20 35 35 1 32.5 
35 6 1 6 0 0 0 0 0 0 0 0 20 10 20 10 20 10 25 15 30 30 20 20 35 35 30 30 50 40 20 20 90 30 1 35 
36 36 0 0 0 0 0 0 0 0 0 0 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 15 20 20 40 20 1 27.5 
37 6 1 6 0 0 0 0 0 0 0 0 15 15 15 15 15 15 15 15 10 10 10 10 10 10 15 15 10 10 10 10 15 15 0 12.5 
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1 25 2 1 1 1 1 1 131 2 20.9 2 0 192 1 20 1 2 0 
2 37.5 2 1 1 1 1 1 98.6 2 31.5 2 0 200.6 1 1 0 5 0 
3 25 2 1 1 1 1 1 148 2 27.1 2 0 1 0 1 0 2 0 
4 20 2 1 1 1 1 1 99.3 2 30.5 2 0 179 1 89 1 2 0 
5 25 2 1 1 2 1 1 103 2 20.5 2 0 1 0 1 0 2 0 
6 37.5 2 1 1 1 1 1 93.4 2 18.8 2 0 212 1 190 1 31 1 
7 22.5 2 1 1 1 1 1 139 2 43.8 3 0 40 1 2 0 2 0 
8 37.5 1 1 1 1 1 1 0 0 0 0 3 0 3 0 3 0 3 
9 22.5 1 1 1 1 1 1 113 2 39.6 2 0 6 0 4 0 2 0 
10 20 2 1 2 2 1 1 54.5 1 9.74 1 0 217 1 9 0 3 0 
11 55 3 1 1 2 0 0 163 2 28 2 0 1 0 1 0 6 0 
12 25 7 1 1 1 1 1 113 2 29.6 2 0 119 1 262 1 4 0 
13 35 2 1 1 1 1 1 138 2 35.2 2 0 110 1 319 1 0 3 
13 25 2 1 1 1 1 1 101 2 13.6 2 0 214 1 248 1 3 0 
15 20 2 1 1 1 1 1 107 2 14.7 2 0 2 0 1 0 6 0 
16 25 2 1 1 1 1 1 0 0 0 0 0 0 3 0 3 0 3 
17 25 2 1 1 1 1 1 165 2 29.9 2 0 249 1 0 0 6 0 
18 15 1 1 3 1 0 1 103 2 34.7 2 0 1 0 1 0 3 0 
19 25 0 0 1 1 1 1 123 2 25.3 2 3 192 1 1 0 3 0 
20 15 2 1 1 1 1 1 122 2 18 2 0 65 1 2 0 3 0 
21 25 0 0 1 1 0 0 118 2 20.6 2 0 2 0 1 0 0 3 
22 27.5 0 0 1 1 1 1 150 2 22.6 2 0 153 1 4 0 2 0 
23 35 2 1 5 1 0 0 120 2 23.9 2 0 189 1 265 1 4 0 
24 12.5 0 0 1 1 1 1 142 2 38.6 2 0 1 0 1 0 3 0 
25 15 1 1 3 5 1 1 121 2 31.8 2 0 1 0 1 0 2 0 
26 20 4 1 1 1 1 1 113 2 21.5 2 0 50 1 3 0 4 0 
27 17.5 2 1 1 1 1 1 162 2 25.8 2 3 1 0 1 0 3 0 
28 5 0 0 1 1 1 1 103 2 17.4 2 0 123 1 176 1 1 0 
29 20 2 1 1 1 1 1 126 2 39.7 2 3 200 1 257 1 4 0 
30 85 8 1 1 4 0 0 164 2 43.4 3 0 1 0 1 0 2 0 
31 20 0 0 1 1 1 1 161 2 41.3 3 3 1 0 1 0 5 0 
32 30 2 1 1 1 1 1 124 2 24.1 2 3 76 1 3 0 1 0 
33 37.5 2 1 1 1 0 0 0 0 0 0 3 67 1 2 0 0 0 
34 32.5 2 1 2 4 0 0 122 2 10.7 2 0 215 1 159 1 0 3 
35 25 4 1 3 1 1 1 130 2 24.3 2 0 167 1 18 0 0 3 
36 20 0 0 1 1 1 1 103 2 24.7 2 3 191 1 222 1 21 1 
37 12.5 0 0 1 1 1 1 137 2 24.1 2 0 216 1 268 1 2 0 
 
